These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35924681)

  • 21. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
    Boman H; Hedelin H; Holmäng S
    J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The usefulness of urinary FDP in the diagnosis of bladder cancer: comparison with NMP22, BTA and cytology].
    Oeda T; Manabe D
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):1-5. PubMed ID: 11235137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tumor marker tests in bladder cancer].
    Feil G; Stenzl A
    Actas Urol Esp; 2006 Jan; 30(1):38-45. PubMed ID: 16703728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.
    Kelly JD; Dudderidge TJ; Wollenschlaeger A; Okoturo O; Burling K; Tulloch F; Halsall I; Prevost T; Prevost AT; Vasconcelos JC; Robson W; Leung HY; Vasdev N; Pickard RS; Williams GH; Stoeber K
    PLoS One; 2012; 7(7):e40305. PubMed ID: 22792272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
    Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
    Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of Atypical Cell Parameter in the Surveillance of Patients with NMIBC; Initial Outcomes of a Single Center Prospective Study.
    Karaburun MC; Özkaya MF; Ergüder Bİ; Süer E
    J Med Syst; 2023 Mar; 47(1):41. PubMed ID: 36976368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Urinary tumor marker for urothelial cancer].
    Ohtani M; Iwasaki A; Shiraiwa H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma.
    Kiyokawa H; Yasuda H; Oikawa R; Okuse C; Matsumoto N; Ikeda H; Watanabe T; Yamamoto H; Itoh F; Otsubo T; Yoshimura T; Yoshida E; Nakagawa M; Koshikawa N; Seiki M
    Cancer Sci; 2017 Jul; 108(7):1432-1439. PubMed ID: 28418226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection.
    Miyanaga N; Akaza H; Tsukamoto S; Shimazui T; Ohtani M; Ishikawa S; Noguchi R; Manabe F; Nishijima Y; Kikuchi K; Sato K; Hayashi H; Kondo F; Shiraiwa H; Aoyama O
    Int J Clin Oncol; 2003 Dec; 8(6):369-73. PubMed ID: 14663639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of urine NMP22 point-of-care test for the screening of bladder cancer].
    Ihm CH; Kim JM; Sohn YH
    Korean J Lab Med; 2007 Apr; 27(2):106-10. PubMed ID: 18094560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of screening methods in the detection of bladder cancer.
    Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
    J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NMP22 in transitional cell carcinoma of the urinary bladder.
    Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL
    J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R; Huber P; Blöchlinger A; Stoffel F; Dalquen P; Gasser TC; Lehmann K
    J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
    Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
    BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
    Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
    World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
    D'Andrea D; Soria F; Zehetmayer S; Gust KM; Korn S; Witjes JA; Shariat SF
    BJU Int; 2019 Jun; 123(6):959-967. PubMed ID: 30653818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.